NEW YORK, December 28, 2004 Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) approved the use of its extended-spectrum antifungal VFEND (voriconazole; IV for injection, tablets, and oral suspension) for the treatment of candidemia in nonneutropenic patients (those without low white blood cell counts) and the following Candida infections: disseminated (deep tissue) infections in skin and infections in abdomen, kidney, bladder wall, and wounds. Bloodstream infections caused by Candida (candidemia) are the fourth most common type of hospital-acquired bloodstream infections in the Unites States and have the highest mortality rate.
According to the U.S. Centers for Disease Control and Prevention, candidemia occurs in eight of every 100,000 persons per year. Those at risk for disseminated Candida infections include patients with compromised immune systems such as stem-cell and organ-transplant recipients, surgical patients, and critically ill patients in the intensive care unit.
"This new approval is important because there is now clinical proof of VFEND's first-line systemic efficacy against a broad range of serious fungal infections," said Dr. Ann Kolokathis, Vice President US Medical at Pfizer. "VFEND is effective against clinically relevant Candida species including hard-to-treat pathogens, such as C glabrata and C krusei, which cause these life threatening infections. In addition, VFEND is available in IV and oral formulations, offering dosing convenience for patients and potentially resulting in cost savings and shorter hospital stays."
The basis for the approval of VFEND to treat candidemia in nonneutropenic patients was a randomized, open-label, comparative, multi-center study involving 422 patients worldwide. Patients were randomized two-to-one to receive either VFEND (n = 283) or amphotericin B followed by fluconazole (n = 139). A data review committee, comprised of fungal disease experts, assessed clinic
'"/>
Contact: Vanessa Aristide
212-733-3784
Edelman Public Relations
28-Dec-2004
Page: 1 2 Related medicine news :1.
FDA approves Pfizers Lyrica for the treatment of the two most common forms of neuropathic pain2.
New data sets survival benchmark for Pfizers ELLENCE3.
Pfizers VFEND (R) as effective in treating Candidemia as two-drug standard of care, study shows4.
Pfizers VFEND(R) receives FDA approval for treatment of esophageal candidiasis5.
Pfizers ZYVOX(TM) more effective than vancomycin in treating complicated SSTIs caused by MRSA6.
Professionalism and professional ethics in medicine7.
Mountaineering doctors hike medicine to new heights with Xtreme Everest8.
Liverpool to lead 20M Department of Health initiative to develop medicines for children9.
Computational tool predicts how drugs work in cells, advancing efforts to design better medicines10.
Telemedicine revolution is disappearing from the NHS11.
Transport system smuggles medicines into brain